Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

This study is testing a new chemotherapy drug (mitoxantrone hydrochloride liposome) combined with another cancer drug (famitinib) for people with nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat) that has come back or spread after prior treatment, including treatment with immunotherapy drugs. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with nasopharyngeal carcinoma confirmed by tissue biopsy - Your cancer has come back or spread and has stopped responding to prior treatment including immunotherapy - You are generally healthy enough to carry out daily activities - Your liver, kidneys, blood counts, and heart are functioning adequately **You may NOT be eligible if...** - Your cancer could still be surgically removed - You are allergic to liposomal drugs or the study drugs - You have received high cumulative doses of certain heart-affecting chemotherapy drugs - You have uncontrolled high blood pressure or significant heart disease - You are pregnant or breastfeeding - You have HIV, active Hepatitis B or C - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.